Agios Pharmaceuticals, Inc. (AGIO) Financial Analysis & Valuation | Quarter Chart

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzym... more
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development o... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$2.16BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEOBrian Goff
IPO Date2013-07-24CAGR6.68%
Employees540Websitewww.agios.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
AGIO chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
EV$2.39BP/E-5.02Forward P/E-7.97PEG
P/S20648.21P/B1205.5P/CF-3542.44P/FCF-3542.44
Sales$66.05MSales 1Y78.34%Sales 3Y247.31%Sales 5Y-43.11%
EPS$-7.25EPS 1YEPS 3YEPS 5Y
Sales QoQ3.9%EPS QoQ-8.65%Sales QoQ Avg26.27%EPS QoQ Avg3.01%
Gross Margin82.07%Operating Margin-719.97%Profit Margin-639.84%ROCE-42.23%
ROA-36%ROE-34%Altman Z Score15.74Piotroski Score3
Current Ratio14.19Quick Ratio13.59Cash Ratio1.93Op. CF Ratio-2.02
Debt/Equity0.03Debt/Assets0.03Lt Debt/Equity0.02Lt Debt/Cap.
Intrst Cov.Inventory Turnover0.34Asset Turnover0.06Receivables Turnover4.09
Enterprise Value$2.39BP/E Ratio-5.02
Forward P/E-7.97PEG Ratio
P/S Ratio20648.21P/B Ratio1205.5
P/CF Ratio-3542.44P/FCF Ratio-3542.44
EPS$-7.25EPS Growth 1Y
EPS Growth 3YEPS Growth 5Y
Revenue Growth 1Y78.34%Gross Margin0.82%
Operating Margin-7.2%Profit Margin-6.4%
ROE-0.34%ROA-0.36%
ROCE-0.42%Current Ratio14.19
Quick Ratio13.59Cash Ratio1.93
Debt/Equity0.03Interest Coverage
Altman Z Score15.74Piotroski Score3

Agios Pharmaceuticals, Inc. (AGIO) valuation & financials

Agios Pharmaceuticals, Inc. (AGIO) has a market capitalization of $2.16B and trades at a price-to-earnings ratio of -5.0. It operates in the Healthcare sector (Biotechnology).

Agios Pharmaceuticals, Inc.'s revenue grew +78.3% over the last year.

Agios Pharmaceuticals, Inc.'s next earnings report is scheduled for July 30, 2026; analysts estimate EPS of $-1.67.

📈 Analysts estimate AGIO EPS of $-1.67 for the upcoming quarter. See Agios Pharmaceuticals, Inc. revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

Agios Pharmaceuticals, Inc. (AGIO) — frequently asked questions

When does Agios Pharmaceuticals, Inc. (AGIO) report earnings next?

Agios Pharmaceuticals, Inc. is expected to report earnings on July 30, 2026. Analysts estimate EPS of $-1.67.

What is Agios Pharmaceuticals, Inc.'s market cap?

Agios Pharmaceuticals, Inc. (AGIO) has a market capitalization of $2.16B.

What is AGIO's P/E ratio?

Agios Pharmaceuticals, Inc. trades at a price-to-earnings ratio of -5.0, with trailing twelve-month EPS of $-7.25.

How fast is Agios Pharmaceuticals, Inc. growing?

Agios Pharmaceuticals, Inc.'s revenue grew +78.3% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)